- Home
- LLYVK vs HALO Comparison
LLYVK vs HALO Comparison
Compare LLYVK & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LLYVK | HALO |
|---|---|---|
| Founded | 1991 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6B | 7.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | LLYVK | HALO |
|---|---|---|
| Price | $83.52 | $67.61 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $73.33 |
| AVG Volume (30 Days) | 495.8K | ★ 2.2M |
| Earning Date | 02-27-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 56.68 |
| EPS | N/A | ★ 4.74 |
| Revenue | $11,218,000.00 | ★ $1,242,852,000.00 |
| Revenue This Year | N/A | $34.83 |
| Revenue Next Year | $9.71 | $24.84 |
| P/E Ratio | ★ N/A | $14.56 |
| Revenue Growth | N/A | ★ 31.19 |
| 52 Week Low | $60.55 | $47.50 |
| 52 Week High | $102.62 | $79.50 |
Technical Indicators
Market Signals| Indicator | LLYVK | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 48.49 | 52.99 |
| Support Level | $82.32 | $67.95 |
| Resistance Level | $85.61 | $69.48 |
| Average True Range (ATR) | 2.26 | 1.61 |
| MACD | 0.13 | 0.58 |
| Stochastic Oscillator | 51.25 | 77.29 |
Price Performance
Historical ComparisonAbout LLYVK Liberty Media Corporation
Liberty Live Group would be engaged in the operations of Live Nation, and Liberty Media's planning for that group is to maximize the value of its investment in that company and the other assets attributed to the Liberty Live Group and to use the new Liberty Live common stock to make strategic acquisitions or for other capital raising initiatives.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.